NL-OMON20839招募中不适用
Acute myeloid leukemia and myelodysplastic syndrome: parenteral-, enteral- and only oral nutrition during remission induction treatment
Maxima MC0 个研究点目标入组 180 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Adult patients (= 18 years), newly diagnosed with AML or MDS who will start with intensive remission induction chemotherapy
排除标准
- •Patients with cognitive disorders or severe emotional instability
- •Patients who are unable to speak, understand or read the Dutch language.
研究者
相似试验
尚未招募
2 期
AMLM22/D3 - The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in patients with acute myeloid leukaemia in first complete remission.Acute Myeloid Leukaemia (AML)Cancer - Leukaemia - Acute leukaemiaACTRN12621000246886Australian Leukaemia and Lymphoma Group (ALLG)50
招募中
2 期
AMLM22/D2-The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in subjects with acute myeloid leukaemia in first complete remission. Domain 2 is investigating the safety and efficacy of Venetoclax as a maintenance therapy alone or in combination with low dose cytarabine (LDAC).Acute Myeloid Leukaemia (AML)Cancer - Leukaemia - Acute leukaemiaACTRN12619000280101Australian Leukaemia and Lymphoma Group (ALLG)75
进行中（未招募）
不适用
Treatment for acute myeloid leukemia (AML) during its first complete remision with the monoclonal antibody Mylotarg ® (anti-CD33/calicheamicina) pre- and post- autologous transplant of hematopoietic stem cellsAcute myeloid leukemia (AML) during its first complete remision and with high relapse risk, pre- and post- autologous hematopoiteic transplantEUCTR2005-000640-91-ESInstitut de Recerca Hospital Sta. Creu i St. Pau20
终止
2 期
AMLM22/D1: The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in patients with acute myeloid leukaemia in first complete remission.Acute myeloid leukaemia (AML)Cancer - Leukaemia - Acute leukaemiaACTRN12619000248167Australian Leukaemia and Lymphoma Group (ALLG)5
招募中
不适用
Acute Myeloid Leukemia Multimodal GenomicsCTRI/2019/04/018782Tata Trusts